Prenatal and postpartum zidovudine adherence among pregnant women with HIV - Results of a MEMS substudy from the perinatal guidelines evaluation project
Prenatal and postpartum zidovudine adherence among pregnant women with HIV - Results of a MEMS substudy from the perinatal guidelines evaluation project
复制标题
DOI：
10.1097/00126334-200207010-00007
复制
发表时间：
2002-07-01
期刊：
影响因子：
--
通讯作者：
Koenig, LJ
中科院分区：
文献类型：
--
作者：
Ickovics, JR;Wilson, TE;Koenig, LJ
在怀孕期间坚持艾滋病毒治疗方案可能会影响消除垂直传播的努力，并影响出现抗药性艾滋病毒株，从而影响产妇健康和垂直传播耐药株的风险。研究目标是记录围产期对齐多夫定(ZDV)的依从性。在公立诊所就诊、服用ZDV并愿意使用药物事件监测系统(MEMS)帽的HIV孕妇参与了这项遵守情况的子研究。53名妇女被纳入产前分析：然而，19名妇女被排除在产后分析之外，因为医疗记录未能证实产后孕妇对ZDV的处方。ZDV的依从性，定义为妊娠最后3周内每天服用/处方的剂量，极低(平均50.0%)，产后3周显著下降(平均=34.1%)(p=004)，临床上必须强调在怀孕期间，特别是在母亲自己照顾ZDV的情况下，加强依从性。
Adherence to HIV treatment regimens during pregnancy may affect efforts to eliminate vertical transmission and influence the emergence of drug-resistant HIV strains that can affect maternal health and the risk of vertically-transmitted resistant strains. Study objectives were to document patterns of adherence to zidovudine (ZDV) during the perinatal period. Pregnant women with HIV who were seen at public clinics, taking ZDV, and willing to use Medication Event Monitoring Systems (MEMS) caps participated in this adherence substudy. Fifty-three women were included in prenatal analyses: however, 19 women were excluded from postnatal analyses because medical records failed to confirm a postpartum maternal prescription for ZDV. Adherence to ZDV, defined as doses per day taken/prescribed during the last 3 weeks of pregnancy, was extremely low (mean 50.0%), and declined significantly 3 weeks postpartum (mean = 34.1%) (p = 004), Clinical emphasis must be placed on enhancing adherence during and particularly after pregnancy when ZDV is continued for a mother's own care.